Abstract
The prior combined analysis of the SOFT and TEXT trials (N Engl J Med 2014; 371:107) showed that disease-free survival was improved with the aromatase inhibitor (AI) exemestane plus ovarian function suppression (OFS) versus tamoxifen plus OFS in premenopausal women with hormone-receptor-positive breast cancer. Now, investigators have conducted a prospective study of patients in the SOFT trial to determine what percentage of those …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
